SCHEDULE: Venrock Entities Divest enGene Holdings Shares

Multiple Venrock-affiliated entities have reported a complete divestment of their holdings in enGene Holdings Inc. as of June 30, 2026.

Summary

• The filing indicates that several entities affiliated with Venrock Healthcare Capital Partners have ceased to beneficially own any shares of enGene Holdings Inc. as of June 30, 2026.
• This includes Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, and VHCP Management EG, LLC.
• Individual reporting persons Nimish Shah and Bong Koh also report no beneficial ownership.
• All reporting persons have certified that the securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the complete divestment of shares reported by the filing entities, indicating a lack of confidence or strategic shift away from the company.

Negatives

• All reporting persons have zero shares beneficially owned, indicating a complete exit from any investment in enGene Holdings Inc.
• This complete divestment suggests a potential lack of confidence in the company's future prospects by these significant investors.

Risks

• The complete divestment by multiple Venrock-affiliated entities could signal underlying issues or a negative outlook on enGene Holdings Inc.'s future performance.
• A significant reduction in institutional ownership can sometimes lead to increased stock price volatility.

Future Outlook

The filing does not contain forward-looking statements or guidance from the company. The reporting persons' actions suggest a negative outlook from their perspective.

Industry Context

StockSavvy.ai notes that significant divestments by investment firms can be a strong signal to the market, often preceding or coinciding with negative news or a reassessment of a company's valuation within the biotechnology or healthcare sector.

Stakeholder Impact

• Shareholders may view this divestment negatively, potentially impacting share price due to the reduced institutional support and perceived lack of confidence.
• The company's management may need to address the reasons for this significant exit by key investors.

Key Dates

Recommendation

The complete divestment of shares by multiple Venrock-affiliated entities, as reported in this Schedule 13G filing, indicates a significant loss of confidence in enGene Holdings Inc. This suggests a negative outlook on the company's future performance and potential value, warranting a sell recommendation for investors.

Keywords

enGene Holdings, Schedule 13G, Venrock Healthcare Capital Partners, Divestment, Shareholder, Ownership, Securities Exchange Act